Skip to Content

Midodrine Pregnancy and Breastfeeding Warnings

Midodrine is also known as: Orvaten, ProAmatine

Medically reviewed on February 15, 2017

Midodrine Pregnancy Warnings

Animal studies have revealed increased rate of embryo resorption, reduced fetal body weight, and decreased fetal survival. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended and this drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Comments: Adequate methods of contraception should be encouraged.

See references

Midodrine Breastfeeding Warnings

Use should be avoided; otherwise, caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide